Together, these results provide a molecular explanation for the poor clinical outcomes observed in SSTR2high HCC patients, suggesting that SSTR2 expression is intricately linked with a loss of cell adhesion, EMT activation, and tumor invasiveness, and may serve as a surrogate indicator of aggressive genomic alterations in liver cancer. The gene discussed is SSTR2; the disease is hepatocellular carcinoma.